NATERA INC (Common Stock) – ticker 45E (NTRA)
NTRA's Signatera CDx Wins FDA Nod in Muscle-Invasive Bladder Cancer
Natera wins FDA approval for Signatera CDx in bladder cancer, marking the first blood-based MRD companion diagnostic milestone.
Natera Q1 Earnings Call Highlights
Natera NASDAQ: NTRA reported first-quarter 2026 revenue of $697 million, up 39% year over year, as the company delivered more than 1 million total units in a single quarter for the first time. Chief Executive Officer Steve Chapman said strong performance in women's health and another record quarter in oncology drove the results, while Chief Financial Officer Michael Brophy highlighted continued improvement in realized pricing and reimbursement dynamics.
Natera (NTRA) Reports Q1 Loss, Tops Revenue Estimates
Natera (NTRA) came out with a quarterly loss of $0.56 per share versus the Zacks Consensus Estimate of a loss of $0.53. This compares to a loss of $0.5 per share a year ago.
Natera, Inc. (NTRA) Q1 2026 Earnings Call Transcript
Natera, Inc. (NTRA) Q1 2026 Earnings Call Transcript
Natera (NTRA) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
While the top- and bottom-line numbers for Natera (NTRA) give a sense of how the business performed in the quarter ended March 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Natera Looks Compelling As Oncology Testing Momentum Keeps Building
NTRA's oncology franchise, led by Signatera MRD testing, is the main bull case at this point. As long as they keep building on their testing volumes, I believe this should support a long runway in cancer monitoring and recurrence detection. NTRA's 2025 also included new product launches and added Medicare coverage, advanced early cancer detection, and broadened its molecular diagnostics portfolio.
Natera, Inc. $NTRA Position Reduced by Bank of Hawaii
Bank of Hawaii reduced its stake in shares of Natera, Inc. (NASDAQ: NTRA) by 18.6% in the undefined quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 17,835 shares of the medical research company's stock after selling 4,072 shares during
Natera, Inc. (NTRA) Presents at Leerink Global Healthcare Conference 2026 Transcript
Natera, Inc. (NTRA) Presents at Leerink Global Healthcare Conference 2026 Transcript
Natera, Inc. (NTRA) Presents at 47th Annual Raymond James Institutional Investor Conference Transcript
Natera, Inc. (NTRA) Presents at 47th Annual Raymond James Institutional Investor Conference Transcript
Natera, Inc. (NTRA) Presents at TD Cowen 46th Annual Health Care Conference Transcript
Natera, Inc. (NTRA) Presents at TD Cowen 46th Annual Health Care Conference Transcript
Natera, Inc. (NTRA) Q4 2025 Earnings Call Transcript
Natera, Inc. (NTRA) Q4 2025 Earnings Call Transcript
Natera (NTRA) Tops Q4 Earnings and Revenue Estimates
Natera (NTRA) came out with quarterly earnings of $0.35 per share, beating the Zacks Consensus Estimate of a loss of $0.46 per share. This compares to a loss of $0.41 per share a year ago.
